EHP-102

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

EHP-102, also known as VCE-003.2, is a cannabinoid CB 2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease. It is taken orally. The drug is a derivative of cannabigerol (CBG). It is under development by Emerald Health Sciences. As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.

EHP-102, also known as VCE-003.2, is a cannabinoid CB 2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease. It is taken orally. The drug is a derivative of cannabigerol (CBG). It is under development by Emerald Health Sciences. As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369638246 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.